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OBJECTIVE: To determine whether there is an association between serum ischemia-modified albumin and the risk
factor profile in type 2 diabetic patients with peripheral arterial disease and to identify the risk markers for
peripheral arterial disease.
METHODS: Participants included 290 patients (35.2% women) with type 2 diabetes. The ankle-brachial pressure
index was measured using a standard protocol, and peripheral arterial disease was defined as an ankle-brachial
index ,0.90 or $1.3. The basal ischemia-modified albumin levels and clinical parameters were measured and
analyzed. The risk factors for peripheral arterial disease were examined by multiple logistic analyses.
RESULTS: Age, systolic blood pressure, total cholesterol, low-density lipoprotein cholesterol, urine albumin,
homocysteine, and ischemia-modified albumin were significantly higher in patients with peripheral arterial disease
than in disease-free patients (p,0.05), while ankle-brachial index was lower in the former group (p,0.05). Ischemia-
modified albumin was positively associated with HbA1c and homocysteine levels (r=0.220, p=0.030; r=0.446,
p=0.044, respectively), while no correlation was found with ankle-brachial index. Multiple logistic analyses
indicated that HbA1c, systolic blood pressure, homocysteine and ischemia-modified albumin were independent risk
factors for peripheral arterial disease in the diabetic subjects.
CONCLUSION: The baseline ischemia-modified albumin levels were significantly higher and positively associated
with HbA1c and homocysteine levels in type 2 diabetic patients with peripheral arterial disease. Ischemia-modified
albumin was a risk marker for peripheral arterial disease. Taken together, these results might be helpful for
monitoring diabetic peripheral arterial disease.
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INTRODUCTION
Peripheral arterial disease (PAD) is a clinical manifesta-
tion of atherosclerotic arterial occlusive disease that affects
the lower extremities. It is also one of the most severe
complications of type 2 diabetes mellitus (T2DM) and a
major cause of morbidity and mortality; patients with PAD
have an increased risk of vascular events.
1,2 Peripheral
arterial disease affects 8 to 12 million individuals in the
United States and is also prevalent in Europe and Asia.
3-5 A
cluster of conditions that are associated with metabolic
abnormality, such as smoking, advanced age, hypertension,
dyslipidemia, and high levels of homocysteine, are impor-
tant risk factors for PAD. More than 95% of persons with
PAD have one or more cardiovascular disease risk factors.
6-8
In PAD, biomarkers are released into the circulation from
lower extremity arterial beds vascular endothelium. A blood
test for PAD that measures these biomarkers, if sufficiently
sensitive and specific, would be expected to improve recogni-
tion and treatment of affected individuals. Biomarkers for
PAD also might be useful in determining prognosis, the risk
for progression. Both traditional and nontraditional risk
biomarkers are independently associated with PAD,
9 and
monitoring nontraditional risk biomarkers of PAD in diabetes
might be particularly important. Among persons with PAD,
circulating levels of D-dimer is higher 1 to 2 years before death
than in periods more remote from death. D-dimer levels
increase is independently associated with higher mortality in
persons with PAD.
10 In comparison to D-dimer, ischemia-
modified albumin is a relatively new and sensitive biomarker
for evaluating patients with ischemic events, especially for the
earlydiagnosisofmyocardialischemia.
11,12Ischemia-modified
albumin, also called cobalt-binding albumin, is produced as a
result of serum albumin flowing through ischemic tissues and
is a marker of oxidative stress and ischemia, as serum levels of
modified albumin rise in many diseases accompanied by
ischemia.
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1677Whether the modified albumin is associated with sys-
temic atherosclerotic burden is not known. Until now, few
studies in the literature have evaluated ischemia-modified
albumin levels in patients with PAD. We hypothesized that
the modified albumin levels might be affected by ischemia
occurring in PAD and that modified albumin levels could be
useful for the evaluation of hypoxia associated with a low
ankle-brachial pressure index (ABI; ratio of ankle blood
pressure to brachial blood pressure). The ABI is a simple
and reliable means of diagnosing PAD. In this study, we
investigated whether serum ischemia-modified albumin is
associated with the ABI and/or with atherosclerotic risk
factors in T2DM. A secondary objective was to identify
whether serum ischemia-modified albumin is a nontradi-
tional risk marker for PAD.
METHODS
Patients
This study was performed in the department of endocri-
nology of the Affiliated Huai’an Hospital of Xuzhou
Medical College in Huai’an, P.R. China. All participants
gave informed consent. The study was approved by the
Ethics Committee of the hospital, in accordance with the
Declaration of Helsinki. The study included 290 patients
(35.2% women) with T2DM, 110 of whom had coexisting
PAD. The diagnoses of PAD were confirmed by color
Doppler ultrasonography, a diagnosis of PAD was based on
an ABI ,0.9 or $1.3 in either leg, as described in previous
studies.
3-5
The PAD group consisted of 68 males and 42 females
between 52 and 78 years old. The non-PAD group consisted
of 120 males and 60 females between 50 and 77 years old. In
addition to age and gender, for each patient we recorded the
blood pressure, diabetes and hypertension duration and
other clinical information. All selected patients were with-
out liver and kidney dysfunction, ischemic events, infection,
and corticosteroid therapy.
Measurements
Blood samples were drawn from all subjects into
vacutainer tubes by venipuncture, centrifuged and stored
at -20˚C for a maximum of four weeks before measurement
of ischemia-modified albumin and homocysteine levels. The
level of modified albumin was measured as previously
described,
13-15 and the results were reported in absorbance
units. For the applied technique of manual ischemia-
modified albumin determination, the intra- and inter-assay
coefficient of variations (CV) were 2.37% and 4.12%,
respectively.
The homocysteine concentration was measured by a
competitive immunoassay kit (Changsha Yikang Institute
of Biological Technology, Changsha, China). The intra- and
inter-assay CVs were 2.68% and 3.32%, respectively. Urine
albumin was measured using a radioimmunoassay kit
(Beijing North Institute of Biological Technology, Beijing,
China). The intra- and inter-assay CVs were 3.37% and
3.07%, respectively.
The HbA1c level was measured on a Bio-Rad Laboratories
Ltd. (Shanghai, China) HbA1c meter. The final HbA1c test
result was calculated from the HbA1c/Hb ratio.
16 The intra-
and inter-assay precisions were CV 2.4% and CV 1.7%,
respectively, and the sensitivity was 0.68 mmol/l for
hemoglobin and 0.71 mmol/l for HbA1c. Plasma glucose,
creatinine, uric acid, total cholesterol, triglycerides, high-
density lipoprotein cholesterol, and low-density lipoprotein
cholesterol were measured by standard procedures.
Statistical Analyses
Statistical analyses were conducted with Statistical
Package for the Social Sciences 11.0 for Windows (SPSS
Inc, Chicago, IL). All quantitative data were expressed as
the mean ¡standard deviation (x ¡ SD). Differences
between groups were analyzed by unpaired Student’s t-
tests and Chi-squared tests. Linear correlation coefficients
between the modified albumin and various parameters
were calculated. The risk factors for PAD were examined by
multiple logistic analyses. A two-tailed p,0.05 was con-
sidered statistically significant.
RESULTS
The clinical results of the survey of the PAD and non-
PAD groups are shown in Table 1. Indexes in the PAD
group, including age, HbA1c, systolic blood pressure, low-
density lipoprotein cholesterol, total cholesterol, urine
albumin, homocysteine, and ischemia-modified albumin,
were higher than those of the non-PAD group (p,0.05). ABI
was lower (p=0.023). There were no significant differences
between the two groups with respect to gender, diastolic
blood pressure, high-density lipoprotein cholesterol, trigly-
cerides, and serum uric acid.
Table 2 shows the correlation between ischemia-modified
albumin levels and age, ABI, and other variables in both
groups. Modified albumin was positively associated with
HbA1c and homocysteine (r=0.220, p=0.030; r=0.446,
p=0.044, respectively), while no correlation was found with
ABI or other variables.
To examine the risk factors to PAD, a multiple logistic
regression analysis with the eight significant variables (age,
HbA1c, systolic blood pressure, low-density lipoprotein
cholesterol, total cholesterol, urine albumin, homocysteine,
and ischemia-modified albumin) was performed. The
results are shown in Table 3. The odds ratios and 95%
confidence intervals for PAD were calculated. The levels of
HbA1c, systolic blood pressure, homocysteine, and mod-
ified albumin were independent risk factors to PAD
(p,0.05).
DISCUSSION
Modified albumin is also a novel indicator of widespread
endothelial damage and ischemia in diabetic patients.
17 In
this study, ischemia-modified albumin levels were mea-
sured, and correlations between the modified albumin and
HbA1c and homocysteine were described. Subjects with
PAD had higher modified albumin levels and lower ABIs
than patients without PAD. The increase in modified
albumin and ABI could indicate an important clinical
anoxic condition.
Recent studies demonstrate that the atherosclerotic
process in the lower extremities in PAD is not confined to
conduit vessels but also affects skeletal muscle flow reserve,
metabolism and endothelial cells.
9 Microvascular endothe-
lial activity and skeletal muscle microvascular flow are
significantly reduced in both the upper and lower extre-
mities of PAD patients.
18,19 The biological explanation of
this association between PAD and ischemia-modified
Ischemia-modified albumin in T2MD with PAD
Shao-gang MA et al.
CLINICS 2011;66(10):1677-1680
1678albumin is related to a decrease in lower extremity
perfusion and oxygenation, thus triggering albumin mod-
ification. High plasma modified albumin levels in diabetic
subjects might indicate subclinical vascular disease.
Microvascular dysfunction is a potential pathophysiological
mechanism of PAD in such cases.
There have been several studies on the modified albumin
in T2DM, but none considered PAD.
20-22 These studies
suggest that the ischemia-albumin molecule in the plasma of
diabetic patients is modified by the chronic hypoxic
conditions provoked mainly by hyperglycemia and oxida-
tive stress. The HbA1c in T2DM is closely associated with
complications, including PAD; higher HbA1c levels reflect a
higher prevalence of severe PAD.
23 Serum modified
albumin in the PAD group was higher than in the non-
PAD group. There was a significant correlation between
modified albumin and HbA1c. When HbA1c increases and
the ABI decreases, the modified albumin might increase at
the same time. The elevated modified albumin levels could
be related to the severity of PAD. Levels of HbA1c and
ischemia-modified albumin might be biomarkers of devel-
oping PAD. Long-term testing and maintenance of HbA1c
and blood pressure in the normal range are of great
importance for the prevention and delay of vascular
complications of T2DM.
Levels of modified albumin were positively correlated
with HbA1c and homocysteine, while no correlative
relationship was found with ABI. As a biochemical marker,
ischemia-modified albumin could be influenced by meta-
bolic factors. The finding of a lack of a correlation with ABI
needs further investigation. The PAD group, which had
higher modified albumin levels, also presented higher levels
of atherosclerotic risk factors, such as poor long-term
glycemic control, hypertension, homocysteine, and dyslipi-
demia. The duration of diabetes, aging, hypertension,
dyslipidemia, and advanced hemoglobin glycosylation are
known risk factors of PAD.
6-8
It has also been shown that homocysteine can cause
endothelial cell damage and vascular disease; Homocysteine
is considered a major independent risk factor for coronary
artery disease, stroke, and PAD. An elevated plasma homo-
cysteine level (.15 mmoL) was associated with an increased
risk of PAD in a meta-analysis of 27 studies.
24 Higher
homocysteine levels were associated with a lower ABI,
independent of conventional risk factors.
25 Few studies to
date have investigated the association of homocysteine levels
with ischemia-modified albumin in PAD. We report here that
homocysteine levels are positively correlated with ischemia-
modified albumin, such that high amounts of modified
albumin might be accompanied by high homocysteine levels.
Table 1 - Clinical parameters of non-PAD and PAD groups with T2DM.
Parameters
non-PAD group
(N=180)
Mean ¡ SD
PAD group
(N=110)
Mean ¡ SD p-value
Gender (women/men)
Age (years)
Ankle-brachial index
Systolic blood pressure (mmHg)
Diastolic blood pressure (mmHg)
HbA1c (%)
Serum creatinine (mmol/L)
Serum uric acid (mmol/L)
Urine albumin (mg/L)
Serum albumin (g/L)
Total cholesterol (mmol/L)
Triglycerides (mmol/L)
High-density lipoprotein cholesterol (mmol/L)
Low-density lipoprotein cholesterol (mmol/L)
Homocysteine (mmol/L)
Ischemia-modified albumin (U/L)
60/120
55.2¡9.2
1.1¡0.12
126.7¡11.0
82.8¡7.5
7.6¡0.3
85.9¡6.1
311.5¡93.0
23.1¡10.0
45.1¡1.1
4.6¡1.4
2.0¡1.2
1.4¡0.3
2.9¡0.8
7.4¡1.3
0.351¡0.13
42/68
62.1¡7.9
0.69¡0.11
139.2¡13.6
89.2¡8.0
9.1¡0.3
92.8¡8.2
341.7¡112.0
120.1¡21.1
44.2¡1.2
5.7¡1.2
2.6¡1.1
1.1¡0.3
4.3¡1.0
11.8¡1.0
0.841¡0.25
0.157
0.015
0.023
0.033
0.702
0.043
0.064
0.657
0.032
0.171
0.035
0.422
0.446
0.036
0.025
0.039
Table 2 - Correlations between the IMA and clinical parameters in the diabetic subjects.
Parameters non-PAD group PAD group
r p-value r p-value
Age (years)
Ankle-brachial index
Systolic blood pressure (mmHg)
Diastolic blood pressure (mmHg)
HbA1c (%)
Serum creatinine (mmol/L)
Serum uric acid (mmol/L)
Urine albumin (mg/L)
Serum albumin (g/L)
Total cholesterol (mmol/L)
Triglycerides (mmol/L)
High-density lipoprotein cholesterol (mmol/L)
Low-density lipoprotein cholesterol (mmol/L)
Homocysteine (mmol/L)
0.001
-0.012
0.063
0.121
0.082
0.056
0.118
0.065
0.085
0.130
0.067
0.013
0.134
0.247
0.985
0.405
0.834
0.092
0.081
0.650
0.227
0.893
0.562
0.703
0.128
0.340
0.280
0.108
0.006
-0.022
0.051
0.180
0.220
0.158
0.208
0.459
0.125
0.031
0.165
0.053
0.037
0.446
0.965
0.315
0.716
0.192
0.030
0.151
0.127
0.696
0.365
0.823
0.229
0.701
0.786
0.044
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1679The biomarkers modified albumin could also help to identify
individuals with complex metabolic conditions who have a
higher risk of suffering from PAD.
CONCLUSION
Measuring the biomarkers ischemia-modified albumin
and homocystein, combined with using the ankle-brachial
index, could be helpful in monitoring and early diagnosis
peripheral arterial disease in T2DM.
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Table 3 - Multiple logistic regression analysis using PAD as a dependent variable with all subjects (n=290).
Parameters Multiple logistic regression analysis
Wald OR p-value 95% CI
Age (years)
Systolic blood pressure (mmHg)
HbA1c (%)
Urine albumin (mg/L)
Total cholesterol (mmol/L)
Low-density lipoprotein cholesterol (mmol/L)
Homocysteine (mmol/L)
Ischemia-modified albumin (U/L)
0.725
4.850
3.801
1.471
1.907
1.273
3.084
3.455
0.640
1.751
1.682
1.002
1.196
0.915
1.250
1.516
0.502
0.023
0.034
0.093
0.068
0.541
0.045
0.040
0.790 - 1.012
1.517 - 3.437
1.867 - 3.640
0.968 - 1.168
1.714 - 2.223
0.918 - 1.515
1.016 - 2.215
1.216 - 2.368
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